JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berthoux, L.
Right arrow Articles by Luban, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berthoux, L.
Right arrow Articles by Luban, J.

 Previous Article  |  Next Article 

Journal of Virology, June 2005, p. 7883-7888, Vol. 79, No. 12
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.12.7883-7888.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Disruption of Human TRIM5{alpha} Antiviral Activity by Nonhuman Primate Orthologues

Lionel Berthoux,1 Sarah Sebastian,1 David M. Sayah,1 and Jeremy Luban1,2*

Departments of Microbiology,1 Medicine, Columbia University College of Physicians and Surgeons, 701 West 168th Street, New York, New York 100322

Received 16 September 2004/ Accepted 15 February 2005


   ABSTRACT
Top
 Abstract
Text
 References
 
TRIM5 is a determinant of species-specific differences in susceptibility to infection by retroviruses bearing particular capsids. Human immunodeficiency virus type 1 (HIV-1) infection is blocked by the alpha isoform of macaque TRIM5 (TRIM5{alpha}rh) or by the product of the owl monkey TRIM5-cyclophilin A gene fusion (TRIMCyp). Human TRIM5{alpha} potently restricts specific strains of murine leukemia virus (N-MLV) but has only a modest effect on HIV-1. The amino termini of TRIM5 orthologues are highly conserved and possess a coiled-coil domain that promotes homomultimerization. Here we show that heterologous expression of TRIM5{alpha}rh or TRIMCyp in human cells interferes with the anti-N-MLV activity of endogenous human TRIM5{alpha} (TRIM5{alpha}hu). Deletion of the cyclophilin domain from TRIMCyp has no effect on heteromultimerization or colocalization with TRIM5{alpha}hu but prevents interference with anti-N-MLV activity. These data demonstrate that TRIM5 orthologues form heteromultimers and indicate that C-terminal extensions alter virus recognition by multimers of these proteins.


   TEXT
Top
 Abstract
 Text
References
 
TRIM5 proteins inhibit the infectivity of a range of different retroviruses in a species-specific fashion (10). The capsid protein (CA) is the viral determinant for susceptibility to this restriction (3, 17). Rhesus macaque TRIM5{alpha} (TRIM5{alpha}rh) restricts human immunodeficiency virus type 1 (HIV-1) replication (18). Human TRIM5{alpha} (TRIM5{alpha}hu) restricts "N-tropic" strains of the murine leukemia virus (N-MLV) (8, 9, 13, 21). In owl monkey cells, HIV-1 is inhibited by TRIMCyp, the product of the TRIM5-cyclophilin (CypA) gene fusion (12, 15). The restriction activities of TRIM5{alpha}rh and TRIMCyp are conferred to nonrestrictive cells upon transduction of the respective cDNAs (15, 18). CypA modulates the restriction of HIV-1 in human and owl monkey cells in opposite ways: HIV-1 CA binding to the CypA domain of TRIMCyp (4, 5) is necessary for inhibition of HIV-1 in owl monkey cells, while "free" CypA appears to protect HIV-1 from restriction in human cells (20).

At the C-terminus of TRIM5{alpha} is a variable SPRY domain that determines the species specificity of restriction (8, 9, 21). In owl monkeys, the SPRY domain was replaced by CypA via L1-mediated retrotransposition (12, 15). TRIM5{alpha} and TRIMCyp both contain a tripartite motif, composed of RING finger, B-Box, and coiled-coil domains (14, 15), that exhibits E3 ubiquitin ligase activity (6, 18). The coiled-coil domain promotes the formation of TRIM5 homomultimers (14). Here we asked whether TRIM5{alpha} or TRIMCyp associates with TRIM5{alpha}hu and alters the antiviral activity of the human protein.

We transduced human rhabdomyosarcoma TE671 cells (19) with previously described LPCX vectors (15, 18) bearing cDNAs for TRIM5{alpha}rh, TRIMCyp, or owl monkey CypA. Cells were also transduced with a vector expressing TRIMStop, a truncated version of TRIMCyp lacking the CypA domain (15). Pools of transduced cells were selected in puromycin and then assessed for susceptibility to infection with HIV-1NL-GFP (2). For each transduced population we also tested the effect on HIV-1 infectivity of cyclosporine A (CsA), a drug that competes with HIV-1 CA for binding to CypA (11). We monitored the percentage of infected (GFP-expressing) cells by fluorescence-activated cell sorting (FACS) and the synthesis of viral cDNA in the infected cells using a Southern blot designed to detect full-length, linear viral cDNA and circular viral cDNAs that form in the nucleus (1, 2, 22).

As expected, both TRIM5{alpha}rh and TRIMCyp inhibited HIV-1 infection of TE671 cells and inhibited HIV-1 cDNA synthesis (Fig. 1). TRIMCyp inhibited HIV-1 replication roughly fivefold more efficiently than TRIM5{alpha}rh, consistent with the higher levels of HIV-1 restriction in owl monkey cells than in macaque cells (1, 15). CsA treatment rescued HIV-1 replication in TRIMCyp-expressing cells, as previously reported (15). CsA also enhanced HIV-1 infection of TE671-TRIM5{alpha}rh, indicating that CsA partially countered HIV-1 restriction when TRIM5{alpha}rh was expressed in human cells. This result was expected, as CsA also counteracts the restriction to HIV-1 in Old World monkey cells (1). At the high multiplicity of infection used here, CsA had little effect on HIV-1 infectivity; in experiments using a lower multiplicity of infection, CsA modestly decreased HIV-1 infection of control TE671 cells, as previously reported (data not shown and reference 20).



View larger version (77K):
[in this window]
[in a new window]
  		FIG. 1. Inhibition of HIV-1 in human TE671 cells expressing owl monkey TRIMCyp or Rhesus macaque TRIM5{alpha}. LPCX-based retroviral vectors were used to transduce the indicated genes into human TE671 cells. Vect, Cyp, TS, TC and T5rh designate, respectively, Vector control, owl monkey CypA, TRIMStop, TRIMCyp, and TRIM5{alpha}rh. These cells were then infected for 16 h with HIV-1NL-GFP (pseudotyped vesicular stomatitis virus G protein) in the presence (+) or absence (-) of CsA (5 µM). One twentieth of the cells were maintained in culture for another day and used to determine the percentage of GFP-positive cells by FACS (bottom of the figure). Total DNA was extracted from the remainder of the cells 16 h after infection, and 5 µg of each DNA sample was analyzed by Southern blotting. The positions of the linear, 1-LTR, and 2-LTR HIV-1 cDNA species are indicated on the left. "Total" DNA refers to a band specific to all HIV-1 cDNA forms, including the integrated DNA.

 
Next, we analyzed MLV replication in TE671-TRIM5{alpha}rh, TE671-TRIMCyp, and the control TE671-vector cells. We infected these cells with N- or B-tropic, GFP-expressing MLV vectors (2) that had identical titers in nonrestrictive Mus dunni tail fibroblasts and were normalized based on infection of these cells (19). In control cells, B-MLV was ~200-fold more infectious than N-MLV (Fig. 2A). As2O3, a drug that counteracts restriction to N-MLV in TE671 cells (2, 9), specifically increased N-MLV infectivity by 10-fold or more (Fig. 2). In cells expressing TRIM5{alpha}rh, the N-MLV replication defect was reduced to about 20-fold (Fig. 2A); in cells expressing TRIMCyp, N-tropic restriction was fully abrogated (Fig. 2A). In either case, As2O3 no longer enhanced infectivity, as would be expected for cells lacking the antiviral activity targeting N-MLV.



View larger version (31K):
[in this window]
[in a new window]
  		FIG. 2. TRIMCyp and TRIM5{alpha}rh abrogate the antiviral activity of endogenous TRIM5{alpha}hu. (A) TE671 cells expressing the indicated LPCX-derived constructs were infected with GFP-expressing B-MLV and N-MLV vectors at multiple doses. Cells were infected in the presence or absence of As2O3 (3 µM). Two days later, the percentage of infected cells was determined by FACS. (B) OMK cells were transduced with MIG (Vect) or with MIG-TRIM5{alpha}hu (T5hu) and challenged with DsRed-expressing N-MLV or B-MLV vectors. Two days later, the percentage of infected cells was determined by FACS. (C) OMK/MIG and OMK/MIG-T5hu cells were challenged with HIV-1-derived, DsRed-expressing CSRW vectors in the presence or absence of Cyclosporine A (2.5 µM).

 
We also performed the reciprocal experiment, transducing owl monkey OMK cells with TRIM5{alpha}hu and challenging them with MLV or HIV-1. TRIM5{alpha}hu had only a small (approximately twofold) restrictive effect on the replication of N-MLV and had no effect on B-MLV (Fig. 2B). Restriction of HIV-1 was similar in cells expressing TRIM5{alpha}hu to that in the control cells (Fig. 2C), and HIV-1 replication was rescued by CsA in both cell lines, consistent with previous reports (15, 20). Altogether, the data in Fig. 2 suggest that TRIMCyp is dominant over TRIM5{alpha}hu.

Since TRIMCyp (but not TRIM5{alpha}rh) completely suppressed the antiviral activity of TRIM5{alpha}hu, we further investigated the effects of this orthologue. TRIMStop, a truncated version of TRIMCyp lacking the CypA domain (15), did not affect the capacity of TE671 cells to restrict N-MLV replication (Fig. 3A). To determine if this was because TRIMStop was expressed at lower levels than TRIMCyp, we performed reverse transcription-PCR (RT-PCR) using conventional methods (15). TRIMStop mRNA was expressed at least as well as TRIMCyp mRNA (Fig. 3B); TRIM5{alpha}hu was expressed at similar levels in all three cell lines (Fig. 3B). By using Western blotting, we could not detect TRIM5 protein in the TE671 cell lines, but when 293T cells were transfected with the LPCX plasmids, TRIMStop was expressed at higher levels than TRIMCyp (Fig. 3C).



View larger version (29K):
[in this window]
[in a new window]
  		FIG. 3. Effect of TRIMStop on TRIM5{alpha}hu antiviral activity. (A) TE671-Vector (Vector) cells and TE671-TRIMStop cells were infected with HIV-1NL-GFP (left panel) or with N- and B-MLV (right panel). Two days later, the percentage of infected (GFP-expressing) cells was determined by FACS. (B) Total RNA was prepared from TE671-Vector (Vect), TE671-TRIMCyp (TC), and TE671-TRIMStop (TS), and RT-PCR was used to detect endogenous TRIM5{alpha} or TRIMCyp/TRIMStop. RT was performed in the presence (+) or absence (-) of reverse transcriptase. (C) 293T cells were transfected with LPCX (Vect), LPCX-TRIMCyp (TC), or LPCX-TRIMStop (TS), and Western blotting was performed using an antibody specific to TRIM5.

 
TRIM5 homomultimerization is promoted by the coiled-coil domain (14), which TRIMCyp also possesses. We hypothesized that the different TRIM5 orthologues heteromultimerize with each other and that TRIMStop did not interfere with TRIM5{alpha}hu activity because these particular proteins are incapable of interacting. We used the yeast two-hybrid system to analyze interactions between TRIMStop, TRIMCyp, TRIM5{alpha}hu, TRIM5{alpha}rh, HIV-1 Gag, and huTRIMStop, a version of TRIM5{alpha}hu which, like TRIMCyp, lacks the C-terminal SPRY domain. Fusions of these proteins with LexA and/or B42 were constructed, and the interactions between fusion proteins were analyzed using a previously described system (7) in which reporter gene ß-galactosidase activity was assessed with a quantitative assay (16). TRIMCyp interacted equally well with TRIMCyp, TRIM5{alpha}rh, TRIM5{alpha}hu, TRIMStop, huTRIMStop, and HIV-1 Gag (Fig. 4A). Though TRIMStop was not able to interact with Gag, presumably because the CypA domain was deleted, this protein was as competent as TRIMCyp in interactions with each of the TRIM5 orthologues.



View larger version (43K):
[in this window]
[in a new window]
  		FIG. 4. TRIMCyp and TRIMStop both bind TRIM5{alpha}hu. (A) Yeast two-hybrid system. TRIM5{alpha}hu, TRIM5{alpha}rh, TRIMCyp, TRIMStop, huTRIMStop, and HIV-1 Gag were fused to lexA. TRIMCyp and TRIMStop were expressed in fusion with the B42 activation domain. Pairs of fused LexA and B42 expression plasmids were transformed into Saccharomyces cerevisiae strain EGY48. For each transformant, ß-galactosidase activity for three colonies is reported in Miller units with the standard deviation. (B) Binding in mammalian cells. TRIM5{alpha}hu was fused to GST. 293T cells were transfected with GST or GST-TRIM5{alpha}hu (GST-T5{alpha}) and cotransfected with LPCX (C), LPCX-TRIMCyp (TC), or LPCX-TRIMStop (TS). Thirty-six hours later, the cells were lysed in 50 mM Tris-Cl (pH 8.0), 150 mM NaCl, 1% NP40, 0.1% SDS, and GST was pulled down using glutathione-coated Sepharose beads (Pharmacia). One percent of the pre-pull-down lysate and 25% of the bound proteins were analyzed by Western blotting, using polyclonal antibodies directed against TRIM5, cyclophilin A, or GST.

 
To investigate TRIM5:TRIMCyp heterodimerization in mammalian cells, we expressed TRIM5{alpha}hu in fusion with glutathione-S-transferase (GST) and transfected 293T cells with either GST or GST-TRIM5{alpha}hu. These cells were cotransfected with the LPCX plasmid constructs described above that express TRIMCyp or TRIMStop. GST pull down on glutathione-Sepharose beads (Sigma) followed by Western blotting with anti-TRIM5 antibody showed that both TRIMCyp and TRIMStop associated with TRIM5{alpha}hu (Fig. 4B). The blot was also probed with an anti-cyclophilin A antibody, confirming the identity of TRIMCyp (Fig. 4B).

Finally, to examine the distribution of the tagged proteins in cells by immunofluorescence, we cloned TRIMCyp and TRIMStop into p3xFLAG.CMV (SIGMA), encoding N-terminal FLAG-tagged versions of the two proteins. These constructs were each transfected into TE671 cells and detected with anti-FLAG antibody. Both TRIMCyp and TRIMStop were diffusely distributed in the cytoplasm and concentrated around the nucleus in about half of the cells. TRIM5{alpha}hu, expressed in fusion with GST and detected with anti-GST antibody, was cytoplasmic as well and was partly localized to cytoplasmic bodies as previously reported (14). When TRIMCyp or TRIMStop were coexpressed in the same cells with TRIM5{alpha}hu, both TRIMCyp and TRIMStop showed partial localization to TRIM5{alpha}hu cytoplasmic bodies, suggesting that TRIMCyp and TRIMStop are both capable of heterodimerizing with TRIM5{alpha}hu in cells. Altogether, the results shown in Fig. 4 and 5 show that TRIM5 orthologues from different primate species heteromultimerize with each other and that failure of TRIMStop to block restriction activity of TRIM5{alpha}hu is not due to failure to multimerize.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 5. Colocalization of TRIMCyp and TRIMStop with TRIM5{alpha}hu. TE671 cells were cotransfected with GST-TRIM5{alpha}hu and with 3x FLAG N-terminal-tagged versions of either TRIMCyp or TRIMStop. Thirty-six hours later, cells were fixed with 4% formaldehyde, permeabilized with 0.1% Triton X-100, and probed with antibodies against GST (rabbit polyclonal; Chemicon International) and FLAG (mouse monoclonal; Sigma). Fluorescent staining was done using Alexa488-conjugated goat anti-mouse and Alexa594-conjugated goat anti-rabbit antibodies and Hoechst33342 (all from Molecular Probes) to reveal DNA. Pictures were generated using a Nikon TE300 microscope with the Openlab 3.0 software.

 
In this work we show that TRIM5 proteins from different primate species interact with each other and can interfere with each other's function. The CypA domain of TRIMCyp is necessary for interference with endogenous TRIM5{alpha} (Fig. 3). CsA did not affect interference by TRIMCyp (data not shown), demonstrating that CypA peptidyl-isomerase activity was not relevant for the effect. A likely possibility is that when TRIM5{alpha}hu/TRIMCyp heterodimers are formed, the cyclophilin A domain of TRIMCyp interferes with TRIM5{alpha}hu's ability to recognize the N-MLV target. Perhaps TRIM5{alpha} and TRIMCyp function as multimers, with the TRIM5 C-terminus facing the viral target (consistent with the role of CypA in binding HIV-1 CA). Similar to the results reported here with different TRIM5 orthologues, the gamma isoform of macaque TRIM5 was found to inhibit TRIM5{alpha}rh anti-HIV restriction activity (18).


   ACKNOWLEDGMENTS
 
We thank Joseph Sodroski and Matthew Stremlau for reagents.

This work was funded by National Institutes of Health grant RO1 AI36199 and used core facilities of the Columbia-Rockefeller Center for AIDS Research. L.B. was supported by a fellowship (106524-35-RFHF) from the American Foundation for AIDS Reseach (AmFAR). D.M.S. was supported by the Columbia University College of Physicians and Surgeons Medical Scientist Training Program.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Columbia University College of Physicians and Surgeons, 701 West 168th St., New York, NY 10032. Phone: (212) 305-8706. Fax: (212) 305-0333. E-mail: JL45{at}columbia.edu. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Berthoux, L., S. Sebastian, E. Sokolskaja, and J. Luban. 2004. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J. Virol. 78:11739-11750.[Abstract/Free Full Text]
  2. Berthoux, L., G. J. Towers, C. Gurer, P. Salomoni, P. P. Pandolfi, and J. Luban. 2003. As2O3 enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J. Virol. 77:3167-3180.[Abstract/Free Full Text]
  3. Bieniasz, P. D. 2003. Restriction factors: a defense against retroviral infection. Trends Microbiol. 11:286-291.[CrossRef][Medline]
  4. Braaten, D., C. Aberham, E. K. Franke, L. Yin, W. Phares, and J. Luban. 1996. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J. Virol. 70:5170-5176.[Abstract/Free Full Text]
  5. Colgan, J., H. E. Yuan, E. K. Franke, and J. Luban. 1996. Binding of the human immunodeficiency virus type 1 Gag polyprotein to cyclophilin A is mediated by the central region of capsid and requires Gag dimerization. J. Virol. 70:4299-4310.[Abstract]
  6. Freemont, P. S. 2000. RING for destruction? Curr. Biol. 10:R84-R87.[CrossRef][Medline]
  7. Gyuris, J., E. Golemis, H. Chertkov, and R. Brent. 1993. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell 75:791-803.[CrossRef][Medline]
  8. Hatziioannou, T., D. Perez-Caballero, A. Yang, S. Cowan, and P. D. Bieniasz. 2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5{alpha}. Proc. Natl. Acad. Sci. USA 101:10774-10779.[Abstract/Free Full Text]
  9. Keckesova, Z., L. M. Ylinen, and G. J. Towers. 2004. The human and African green monkey TRIM5{alpha} genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA 101:10780-10785.[Abstract/Free Full Text]
  10. Lee, K., and V. N. KewalRamani. 2004. In defense of the cell: TRIM5{alpha} interception of mammalian retroviruses. Proc. Natl. Acad. Sci. USA 101:10496-10497.[Free Full Text]
  11. Luban, J., K. L. Bossolt, E. K. Franke, G. V. Kalpana, and S. P. Goff. 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73:1067-1078.[CrossRef][Medline]
  12. Nisole, S., C. Lynch, J. P. Stoye, and M. W. Yap. 2004. A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc. Natl. Acad. Sci. USA 101:13324-13328.[Abstract/Free Full Text]
  13. Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski. 2004. TRIM5{alpha} mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA 101:11827-11832.[Abstract/Free Full Text]
  14. Reymond, A., G. Meroni, A. Fantozzi, G. Merla, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballabio. 2001. The tripartite motif family identifies cell compartments. EMBO J. 20:2140-2151.[CrossRef][Medline]
  15. Sayah, D. M., E. Sokolskaja, L. Berthoux, and J. Luban. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430:569-573.[CrossRef][Medline]
  16. Stern, M., R. Jensen, and I. Herskowitz. 1984. Five SWI genes are required for expression of the HO gene in yeast. J. Mol. Biol. 178:853-868.[CrossRef][Medline]
  17. Stoye, J. P. 2002. An intracellular block to primate lentivirus replication. Proc. Natl. Acad. Sci. USA 99:11549-11551.[Free Full Text]
  18. Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853.[CrossRef][Medline]
  19. Towers, G., M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos. 2000. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. USA 97:12295-12299.[Abstract/Free Full Text]
  20. Towers, G. J., T. Hatziioannou, S. Cowan, S. P. Goff, J. Luban, and P. D. Bieniasz. 2003. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat. Med. 9:1138-1143.[CrossRef][Medline]
  21. Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye. 2004. Trim5{alpha} protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA 101:10786-10791.[Abstract/Free Full Text]
  22. Zennou, V., C. Petit, D. Guetard, U. Nerhbass, L. Montagnier, and P. Charneau. 2000. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 101:173-185.[CrossRef][Medline]

Journal of Virology, June 2005, p. 7883-7888, Vol. 79, No. 12
0022-538X/05/$08.00+0     doi:10.1128/JVI.79.12.7883-7888.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berthoux, L.
Right arrow Articles by Luban, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berthoux, L.
Right arrow Articles by Luban, J.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS